Survival Study of Adjuvant Radiotherapy and Chemotherapy after Definitive Surgery of Locally Advanced Esophageal Carcinoma

Zhu, Shuchai; Su, Jian-An; Li, J.; Shen, Wenbin; Liu, Z.; Song, Chunyang; Li, Y.; Wang, Y.

doi:10.1016/j.ijrobp.2011.06.527

Cited by 2 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No evidence showed publication bias for the pooled estimate (Begg's test, P = 0.721; Egger's test, P = 0.595). The exclusion of one study with only available abstract did not alter the results of pooled analysis (RR = 0.94, 95% CI, 0.77 to 1.14; P = 0.52). In order to assess whether surgery plus adjuvant chemotherapy could significantly prolong the 1‐year and 3‐year DFS for patients with esophageal squamous cell carcinoma, three studies which focused on DFS as the primary end‐point were included.…”

Section: Resultsmentioning

confidence: 90%

“…The current meta‐analysis consisted of three RCTs, two prospective historical control studies (Fang et al . published in Chinese with English abstract), and six retrospective control studies (Liu et al . published in Chinese with English abstract).With respect to one RCT having enrolled some patients with palliative resection, only the completely resected patients were included in our analysis.…”

Section: Resultsmentioning

confidence: 99%

“…published in Chinese with English abstract).With respect to one RCT having enrolled some patients with palliative resection, only the completely resected patients were included in our analysis. Two studies were reported in the international conference with only abstracts available, one in the 12th World Congress of the International Society for Diseases if the Esophagus (2010), the other in 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO 2011) . The characteristics of population in all eligible studies were presented in Table .…”

Section: Resultsmentioning

confidence: 99%

“…Eleven studies with 2047 patients in total were eligible, comparing the treatment of surgery plus adjuvant chemotherapy (n = 887) with surgery alone (n = 1160). The current meta-analysis consisted of three RCTs, [3][4][5] two prospective historical control studies 22,23 (Fang et al 23 published in Chinese with English abstract), and six retrospective control studies 8,9,[24][25][26][27] (Liu et al 25 published in Chinese with English abstract).With respect to one RCT having enrolled some patients with palliative resection, 3 only the completely resected patients were included in our analysis. Two studies were reported in the international conference with only abstracts available, one in the 12th World Congress of the International Society for Diseases if the Esophagus (2010), 27 the other in 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO 2011).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…[3][4][5][6][7] However, some studies suggested that adjuvant chemotherapy could significantly improve long-term survival in patients with esophageal squamous cell carcinoma compared with surgery alone. 8,9 Recently, a randomized controlled trial (RCT) (JCOG 9907) demonstrated significantly better OS after preoperative chemotherapy followed by surgery in comparison with postoperative chemotherapy. 10 However, the result of that study was controversial.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies

et al. 2013

View full text Add to dashboard Cite

The effect of adjuvant chemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas is still controversial, and the subgroup of patients who will most likely benefit from the adjuvant chemotherapy on long-term survival has not yet been identified clearly. Studies published from 1995 to May 2012 were searched in Medline, Embase, PubMed, Cancerlit, the Cochrane Library, CNKI and major scientific meetings. Randomized controlled trials and nonrandomized studies comparing surgery plus adjuvant chemotherapy with surgery alone in patients with resectable thoracic esophageal squamous cell carcinomas were included. Eleven studies with a total of 2047 patients were identified, consisting of the adjuvant chemotherapy arm (n = 887) and surgery-alone arm (n = 1160). There was not statistically significant benefit on 3-year overall survival for adjuvant chemotherapy (risk ratio [RR] = 0.89, 95% confidence interval [CI], 0.72 to 1.09; P = 0.25). Adjuvant chemotherapy could significantly prolong the 1-year disease-free survival (DFS) (RR = 0.68, 95%CI, 0.51 to 0.89; P = 0.006), but not 3-year DFS (RR = 0.97, 95%CI, 0.73 to 1.29; P = 0.84). Further analysis showed that patients with stage III-IV diseases could benefit from adjuvant chemotherapy on 3-year overall survival (RR = 0.43, 95%CI, 0.31 to 0.61; P = 0.00001), but not in the case of patients with stageI-IIdiseases (RR = 1.12, 95%CI, 0.65 to 1.93; P = 0.68). Additionally, patients with positive lymph node could benefit on 5-year DFS from adjuvant chemotherapy (RR = 0.79, 95%CI, 0.64 to 0.99; P = 0.04). The modality treatment with adjuvant chemotherapy for patients with squamous cell carcinoma of thoracic esophagus might be determined according to pathological stage or the status of lymph node metastasis.

show abstract

Section: Resultsmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies

et al. 2013

View full text Add to dashboard Cite

show abstract

The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score- matched analysis

Deng

Jiang

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: At present, the primary treatment of esophageal cancer is surgery-based comprehensive treatment, including adjuvant therapy such as chemotherapy and/or radiotherapy. However, the role of adjuvant therapy for esophageal squamous cell carcinoma (ESCC) with pathologically node-negative (pN0) disease is controversial. This study aimed to evaluate the impact of postoperative adjuvant therapy on survival in patients with pN0 ESCC.Methods: Patients with ESCC who underwent R0 esophagectomy in the Department of Thoracic Surgery of Sichuan Cancer Hospital from January 2008 to December 2013 were enrolled. Patients were divided into two groups: a surgery alone (Group S) group or a surgery + adjuvant therapy (Group S + A) group. The primary outcomes were overall survival (OS) and disease-free survival (DFS), and every consecutive case was followed up until death or the last follow-up.Results: A total of 387 patients with ESCC patients who had pN0 were enrolled in the study. After propensity score matching (PSM), each group consisted of 150 patients. In the overall cohort, the 5-year OS (75.6% vs. 69.7%; P=0.004) and 5-year DFS (64.9% vs. 48.2%; P=0.003) rates were higher in Group S + A than in Group S. In the matched samples, the same outcomes were observed (5-year OS: 75.6% vs.

show abstract

Survival Study of Adjuvant Radiotherapy and Chemotherapy after Definitive Surgery of Locally Advanced Esophageal Carcinoma

Cited by 2 publications

References 0 publications

Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies

Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies

The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score- matched analysis

Contact Info

Product

Resources

About